Highlights of 2024

PATENT GRANTED

We’re excited to share an important milestone for our company: Gisens Biotech has been granted its first patent!

One of the first steps we took during our journey was to file for patents in different territories, to strategically deepen the moat that would serve that protects one of our greatest assets, our technological advantage. This achievement validates the novelty and innovation of our technology, while proving that our strategy to invest in IP is, and will continue, to pay off. It also brings us closer to securing patents in other regions, including the United States and Europe, where applications are currently underway.

Reaching this milestone (AR122169B1- granted) proves the dedication of our team and the strength of our R&D efforts. It highlights our steady progress towards delivering a groundbreaking solution.

This is just one step in our journey, and we’re looking forward to achieving more milestones as we work to redefine the future of healthcare.

If you want to learn more about our current IP portfolio, please fill out this form to schedule a meeting.

TECHSTARS IS BACKING GISENS BIOTECH

Last year, we had the incredible honor of being selected by Techstars to become part of their investment porfolio - along with the support of Goff Capital and the city of Fort Worth, this journey in Texas was a transformative experience for Gisens Biotech. Not only did we receive funding to continue developing and enhancing our solution, but we also gained access to an unparalleled ecosystem of support, mentorship, and networking opportunities.

Their guidance helped us:

• Connect with potential partners, opening doors to exciting collaborations

• Initiate our conversations with the FDA for regulatory clearance of our technology.

• Engage with future investors, building relationships for long-term growth.

Being part of this vibrant healthcare innovation hub in the U.S. has been a game-changer and we’re excited to continue building on the momentum created during this program.

BREAKTRHOUGH PUBLICATION

As part of our commitment towards scientific transparency and accountability, we strive to ensure the science and technology behind our remarkable results is not only publicly available but also continuously vetted by third parties and a community of our peers.

We’re excited to share that we’ve published a novel scientific article highlighting the groundbreaking capabilities of our graphene lab-on-a-chip (G-LOC). This innovative biosensing technology delivers over 95% accuracy in testing kidney function biomarkers while being portable and user-friendly, revolutionizing how diagnostics are performed.

In a first-of-its-kind study, G-LOC was tested outside of a controlled lab environment with real human samples and by lay users, achieving results comparable to those of trained professionals. This milestone not only showcases the robustness of our solution but also proves its potential to bring accessible, precise, and rapid diagnostics directly into patients’ hands, delivering on our promise to transform healthcare.

Learn more about our paper here

SHOWCASING OUR INNOVATION

Last year, we had the privilege of presenting our groundbreaking technology at two prestigious events: the BiotechX Conference and Falling Walls, where we were honored with the coveted title of Venture Winner.

At BiotechX, we conducted live demos, demonstrating how our technology not only delivers precise results but is also designed for ease of use by anyone. This hands-on experience allowed us to highlight the accessibility and transformative potential of our solution.

At Falling Walls, we stood alongside some of the world’s most innovative ventures, receiving recognition that reinforces the impact of our work.

These events provided us with invaluable exposure and connections, bringing us closer to realizing our mission of accessible, patient-centric diagnostics.